Next Article in Journal
MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas
Next Article in Special Issue
Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
Previous Article in Journal
Erratum: Benelli, R., et al. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer. Cancers 2020, 12, 971
Previous Article in Special Issue
The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
Article

Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma

1
Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA
2
School of Medicine, University of California San Diego, San Diego, CA 92092, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally.
Cancers 2020, 12(5), 1219; https://doi.org/10.3390/cancers12051219
Received: 11 March 2020 / Revised: 27 April 2020 / Accepted: 7 May 2020 / Published: 13 May 2020
(This article belongs to the Special Issue Liquid Biopsy in Cancer)
Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma. A longitudinal follow-up of a GBM patient with a FGFR3-TACC3 positive glioma revealed the potential of monitoring RNA fusions in plasma. In summary, we report a sensitive RNA-seq-based liquid biopsy strategy to detect RNA level fusion status in the plasma of GBM patients. View Full-Text
Keywords: glioblastoma; gene fusions; liquid biopsy; RNA-seq; extracellular vesicles glioblastoma; gene fusions; liquid biopsy; RNA-seq; extracellular vesicles
Show Figures

Figure 1

MDPI and ACS Style

Wang, L.; Yekula, A.; Muralidharan, K.; Small, J.L.; Rosh, Z.S.; Kang, K.M.; Carter, B.S.; Balaj, L. Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma. Cancers 2020, 12, 1219. https://doi.org/10.3390/cancers12051219

AMA Style

Wang L, Yekula A, Muralidharan K, Small JL, Rosh ZS, Kang KM, Carter BS, Balaj L. Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma. Cancers. 2020; 12(5):1219. https://doi.org/10.3390/cancers12051219

Chicago/Turabian Style

Wang, Lan, Anudeep Yekula, Koushik Muralidharan, Julia L. Small, Zachary S. Rosh, Keiko M. Kang, Bob S. Carter, and Leonora Balaj. 2020. "Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma" Cancers 12, no. 5: 1219. https://doi.org/10.3390/cancers12051219

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop